111266-27-4Relevant articles and documents
Enantioselective Formal C?H Conjugate Addition of Acetanilides to β-Substituted Acrylates by Chiral Iridium Catalysts
Shibata, Takanori,Michino, Masamichi,Kurita, Hisaki,Tahara, Yu-Ki,Kanyiva, Kyalo Stephen
, p. 88 - 91 (2017)
The Ir-catalyzed enantioselective reaction of substituted acetanilides with β-substituted α,β-unsaturated esters provided chiral 3,3-disubstituted propanoates in high yield with good-to-excellent enantiomeric excess (up to 99 % ee). This transformation, i
Application of Transition-Metal Catalysis, Biocatalysis, and Flow Chemistry as State-of-the-Art Technologies in the Synthesis of LCZ696
Gu, Xingxian,Zhao, Jibin,Chen, Like,Li, Yunzhong,Yu, Bo,Tian, Xiangguang,Min, Zhongcheng,Xu, Su,Gu, Huijuan,Sun, Junjie,Lu, Xiaoquan,Chang, Meng,Wang, Xufan,Zhao, Liqun,Ye, Shengqing,Yang, Hongwei,Tian, Yingtao,Gao, Feng,Gai, Yu,Jia, Guanghua,Wu, Jingjing,Wang, Yan,Zhang, Jianghua,Zhang, Xuesong,Liu, Weichun,Gu, Xin,Luo, Xi,Dong, Hai,Wang, Huaimin,Schenkel, Berthold,Venturoni, Francesco,Filipponi, Paolo,Guelat, Bertrand,Allmendinger, Thomas,Wietfeld, Bernhard,Hoehn, Pascale,Kovacic, Nikola,Hermann, Luca,Schlama, Thierry,Ruch, Thomas,Derrien, Nadine,Piechon, Philippe,Kleinbeck, Florian
, p. 6844 - 6853 (2020/06/04)
LCZ696 is a novel treatment for patients suffering from heart failure that combines the two active pharmaceutical ingredients sacubitril and valsartan in a single chemical compound. While valsartan is an established drug substance, a new manufacturing process suitable for large-scale commercial production had to be developed for sacubitril. The use of chemocatalysis, biocatalysis, and flow chemistry as state-of-the-art technologies allowed to efficiently build up the structure of sacubitril and achieve the defined performance targets.
CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES
-
Page/Page column 66; 67, (2018/06/06)
The present invention relates to Compounds of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.